Shionogi and Sciele receive US antitrust clearance
- Posted on 06 October 2008
Shionogi and Sciele Pharma announced that the waiting period under the Hart Scott Rodino Antitrust Improvements Act of 1976 on Shionogi’s indirect wholly owned subsidiary’s cash tender offer for all outstanding shares of common stock of Sciele at a price of $31.00 per share had expired at on September 18, 2008.
Accordingly, the condition to the tender offer concerning the antitrust and competition laws of the US has been satisfied.
The tender offer is currently scheduled to expire on October 3.
The tender offer is being made following to the previously announced agreement of merger among Shionogi, its indirect wholly owned subsidiary, and Sciele.
